ProCE Banner Activity

GRIFFIN: Efficacy and Updated Safety From Phase II Study of Daratumumab + VRd vs VRd Alone for Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
Dara + VRd shows early efficacy and safety for ASCT-eligible patients with newly diagnosed myeloma enrolled in the phase II GRIFFIN trial.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology